Johnson & Johnson Showcases Promising Results for Subcutaneous Amivantamab in Head & Neck Cancer at ESMO 2025
Reuters
Oct 16
Johnson & Johnson Showcases Promising Results for Subcutaneous Amivantamab in Head & Neck Cancer at ESMO 2025
Johnson & Johnson has announced plans to showcase 16 presentations highlighting advances in its solid tumor pipeline at the European Society for Medical Oncology (ESMO) 2025 Congress. The presentations will cover head and neck, lung, bladder, and prostate cancers, focusing on both clinical data and pipeline developments. Notably, the first report of subcutaneous amivantamab will be presented, demonstrating clinical activity in recurrent or metastatic head and neck cancer. Additionally, a new analysis and recent U.S. FDA Fast Track designation for pasritamig in prostate cancer will be highlighted. The results are scheduled to be presented at ESMO 2025, with specific sessions for head and neck cancer data set for October 19 and 20, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.